|
Mar 25
|
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
|
|
Mar 25
|
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
|
|
Mar 19
|
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
|
|
Mar 12
|
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges
|
|
Mar 12
|
Q4 2024 Agenus Inc Earnings Call
|
|
Mar 11
|
Agenus (AGEN) Q4 2024 Earnings Call Transcript
|
|
Mar 11
|
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 11
|
Agenus: Q4 Earnings Snapshot
|
|
Mar 11
|
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
|
|
Feb 24
|
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
|
|
Feb 21
|
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
|
|
Feb 20
|
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 12
|
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
|
|
Nov 7
|
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
|
|
Nov 5
|
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
|
|
Sep 3
|
Agenus to Participate in September Investor Conferences
|
|
Jul 26
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
|
Jul 26
|
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
|
|
Jul 12
|
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
|
|
Jun 28
|
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
|